Nuvectis Pharma (NVCT)
(Delayed Data from NSDQ)
$6.00 USD
-0.17 (-2.76%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $5.98 -0.02 (-0.33%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NVCT 6.00 -0.17(-2.76%)
Will NVCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NVCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVCT
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
NVCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
Other News for NVCT
Nuvectis Pharma Inc Reports Q2 2025 EPS of -$0. ...
Nuvectis Pharma GAAP EPS of -$0.30
Nuvectis Pharma (NVCT) Strengthens Position with Promising Trial Results
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights | ...
Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year